Is Pfizer stock a buy?

Pfizer (PFE) has been analyzed by 7 analysts, with a consensus rating of Hold. 14% of analysts recommend a Strong Buy, 0% recommend Buy, 86% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

Is Pfizer a good buy right now?

The financial health and growth prospects of PFE, demonstrate its potential to outperform the market. It currently has a Growth Score of C. Recent price changes and earnings estimate revisions indicate this would be a good stock for momentum investors with a Momentum Score of A.

Why is Pfizer stock so cheap?

Pfizer's shares, after a year of modest growth, recently fell following a cautious outlook for 2026, emphasizing ongoing challenges. The pharmaceutical powerhouse is facing a significant patent cliff and diminishing demand for COVID-19 products, forecasting future profits below what analysts expect.

What is the future of Pfizer stock?

In 2026, Pfizer expects adjusted earnings per share in the range of $2.80-$3.00, which represents a decline from the 2025 expected range of $3.00 and $3.15 due to the dilutive impact of 3SBio and Metsera acquisitions, lower COVID revenues and higher taxes.

Is Pfizer good long-term?

Pfizer's long-term future could also be much better than its near-term prospects. Management expects that new products and late-stage candidates will help return the company to growth within a few years.

Is Pfizer Stock a Buy Now!? | Pfizer (PFE) Stock Analysis! |

Does Warren Buffett invest in Pfizer?

Berkshire Hathaway's Pfizer Stake

Warren Buffett started to build up the position in Pfizer in Q3 2020. Since then they sold 3.71M shares. The investor sold all their shares in Q4 2020 and doesn't own any shares in Pfizer anymore.

Is Pfizer undervalued or overvalued?

Our Discounted Cash Flow (DCF) analysis suggests Pfizer is undervalued by 56.2%. Track this in your watchlist or portfolio, or discover 868 more undervalued stocks based on cash flows.

Why is PFE stock down so much?

That's arguably one of the chief reasons P&G shares have performed so poorly since November 2024, falling 20% from that peak -- the company's been forced to maneuver rather aggressively in an inflation-riddled environment where consumers are doing more price-conscious shopping (not to mention an environment that now ...

Will Pfizer bounce back?

Promising clinical results in 2026 could set the stage for Pfizer's stock to rebound. However, the company's COVID-19 product and patent cliff challenges could prevent a big bounce this year. Even if Pfizer's stock doesn't rebound in 2026, investors can find some bright spots.

What does Jim Cramer say about Pfizer stock?

Jim Cramer on Pfizer: “I'm Going to Say Just Weak Hold” Pfizer Inc. (NYSE:PFE) is one of the stocks Jim Cramer shed light on.

Is Pfizer a dividend trap?

Despite a massive dividend yield approaching 7% and a series of aggressive multibillion-dollar acquisitions, the market remains skeptical of Pfizer's ability to replace its dwindling COVID-19 revenue and navigate a looming "patent cliff."

Should I keep or sell my shares?

To make sure you hold onto the bulk of any big gain, you'll sometimes have to go on offense and sell some or all of your shares to lock in profits. If you don't, a stock market correction or a downturn in a former leader can wipe out your gains. Even worse, such a decline could turn your profits into a loss.

How much will Pfizer save in 2025?

As of April of this year, Pfizer had lifted its overall savings target to $7.7 billion through 2027. Pfizer has said it expects to realize $4.5 billion of that sum in net cost savings by the end of 2025.

What is the 90% rule in stocks?

The "Rule of 90" in stocks typically refers to two different concepts: the harsh 90-90-90 rule for new traders (90% lose 90% of capital in 90 days) due to lack of strategy, risk management, and emotional control, and Warren Buffett's 90/10 investment rule (90% low-cost S&P 500 index fund, 10% short-term bonds) for long-term investors seeking simplicity and diversification. The first warns against trading pitfalls, while the second promotes a passive, long-term approach to build wealth.

Should I hold or sell Pfizer?

Pfizer (PFE) has been analyzed by 7 analysts, with a consensus rating of Hold. 14% of analysts recommend a Strong Buy, 0% recommend Buy, 86% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

Does Pfizer have a future?

Pfizer anticipates full-year 2026 revenues to be in the range of $59.5 to $62.5 billion, while full-year 2025 revenue guidance(2) is revised to approximately $62.0 billion from the range of $61.0 to $64.0 billion previously.

Why is Pfizer stock struggling?

Some of Pfizer's major products are due to lose patent protection in the next few years. Revenues from COVID products are expected to be approximately $1.5 billion lower than the expected figure for 2025. Excluding COVID-19 products and the LOE cliff, Pfizer expects operational revenue growth of about 4% in 2026.

What stock is the next Nvidia?

This analyst recommends quantum stocks - but patience is required. D-Wave is one quantum company that Mizuho recommends for investors looking to play an emerging trend in computing. Nvidia's stock is up nearly 22,000% over the past 10 years, and up 46,000% over the past 15.

How to turn $10,000 into $100,000 in a year?

Here are the most effective ways to earn money and turn that 10K into 100K before you know it.

1. Buy an Established Business. ...
2. Real Estate Investing. ...
3. Product and Website Buying and Selling. ...
4. Invest in Index Funds. ...
5. Invest in Mutual Funds or EFTs. ...
6. Invest in Dividend Stocks. ...
7. Peer-to-peer Lending (P2P) ...
8. Invest in Cryptocurrencies.

What to invest $1000 in right now?

Nvidia, Amazon, and Dutch Bros are top growth stocks to invest in now. If you've got $1,000 available to start investing that isn't needed for monthly bills, to pay down short-term debt, or to bolster an emergency fund, buying some solid growth stocks across sectors can be a good place to start building a portfolio.